apexianpharma.com
Open in
urlscan Pro
107.180.48.125
Public Scan
Submitted URL: http://apexianpharma.com/
Effective URL: https://apexianpharma.com/
Submission: On September 11 via api from US — Scanned from DE
Effective URL: https://apexianpharma.com/
Submission: On September 11 via api from US — Scanned from DE
Form analysis 2 forms found in the DOM
GET https://apexianpharma.com/
<form method="get" class="search-form navigation-search" action="https://apexianpharma.com/">
<input type="search" class="search-field" value="" name="s" title="Search">
</form>GET https://apexianpharma.com/
<form method="get" class="search-form navigation-search" action="https://apexianpharma.com/">
<input type="search" class="search-field" value="" name="s" title="Search">
</form>Text Content
Search Menu * Home * People * Board Of Directors (BOD) * Leadership Team * Scientific Advisory Board (SAB) * Corporate Summary * Our Values and Culture * Research and Development * Clinical Program * Preclinical Programs * Pipeline * Publications * What is APE1/Ref-1? * News * PR (print) * Video * About Us * Search Skip to content Search Menu * Home * People * Board Of Directors (BOD) * Leadership Team * Scientific Advisory Board (SAB) * Corporate Summary * Our Values and Culture * Research and Development * Clinical Program * Preclinical Programs * Pipeline * Publications * What is APE1/Ref-1? * News * PR (print) * Video * About Us * Search TREATMENT OF LIFE-THREATENING DISEASES MEDIATED BY THE APE1/REF-1 PROTEIN AT APEXIAN, OUR MISSION IS STRAIGHTFORWARD: FIND SAFE AND EFFECTIVE THERAPIES THAT WILL IMPROVE THE LIVES OF PATIENTS WITH A NUMBER OF LIFE-THREATENING AILMENTS Our lead drug candidate – APX3330 – targets the APE1/Ref-1 redox protein, a molecule found in a number of cancers1 as well as playing a role in a variety of inflammation and angiogenesis driven illnesses such as diabetic macular edema (DME), inflammatory bowel disease (ulcerative colitis, Crohn’s disease) and chemotherapy-induced peripheral neuropathy (CIPN). Our experienced team of research scientists and clinical specialists have completed a phase 1 study in patients with advanced cancers. Apexian is now preparing for further development of its lead compound. 1Cancers include; AML, colon, pancreatic, bladder and malignant peripheral nerve sheath tumors (MPNST) OUR SCIENCE IS UNIQUE AND REPRESENTS FIRST-IN-CLASS THERAPEUTIC POTENTIAL. Inhibition of the APE1/Ref-1 redox protein affects signaling pathways critical to cancer cell survival. APX3330 has shown dramatic anti-cancer and anti-inflammatory effects in numerous pre-clinical models of human cancers. Our human studies will evaluate the efficacy and safety of APX3330 in patients with a variety of cancers and inflammation-related conditions that express the APE1/Ref-1 protein. + read more about the R&D at Apexian OUR FOCUS IS ON DEVELOPING DRUGS TARGETING THE APE/1/REF-1 PROTEIN IN MULTIPLE INDICATIONS: ONE DRUG, ONE TARGET, MULTIPLE INDICATIONS. Our clinical plan is focused on developing APX3330 for treatment of diseases controlled by the APE1/Ref-1 protein. These diseases constitute areas of high unmet medical need including cancers of the colon, pancreas, skin, blood, diabetic macular edema, inflammatory bowel disorders and prevention of chemotherapy induced peripheral neuropathy. + Read more about APE1/Ref-1 and Apexian cancer research LATEST APEXIAN NEWS April 8, 2021 // OCUPHIRE INITIATES ZETA-1 PHASE 2 CLINICAL TRIAL INVESTIGATING APX3330 IN DIABETIC RETINOPATHY FARMINGTON HILLS, Mich., GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced that it has screened the first patient in ZETA-1, a Phase 2 trial to evaluate APX3330 in non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (mild PDR). + Read this story + Read all Apexian News www.ApexianPharma.com © 2022 Apexian Pharmaceuticals, Inc. | Indianapolis, Indiana Skip to content * Home * People * Board Of Directors (BOD) * Leadership Team * Scientific Advisory Board (SAB) * Corporate Summary * Our Values and Culture * Research and Development * Clinical Program * Preclinical Programs * Pipeline * Publications * What is APE1/Ref-1? * News * PR (print) * Video * About Us